Modality
ADC
MOA
WEE1i
Target
GLP-1R
Pathway
Cell Cycle
DravetSLEMelanoma
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
Mar 2019
→ Aug 2028
Phase 2Current
NCT04349742
608 pts·Melanoma
2019-03→2028-08·Terminated
608 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-032.3y awayPh3 Readout· Melanoma
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2028-08-03 · 2.3y away
Melanoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04349742 | Phase 2/3 | Melanoma | Terminated | 608 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |